It’s Time You Invested in India
Welcome to CPhI China 2007 and three days of business networking opportunities. With over 1,000 exhibitors and three parallel expositions–CPhI China, ICSE China, and P-MEC China–a unique platform for foreign pharmaceutical companies looking for sourcing and contract manufacturing opportunities in Asia. Last year’s expo saw 18,500 business visitors from 85 countries and a participation of 1,144 companies from 21 countries.
In a globalized business environment India offers a unique opportunity for global investment community–including the pharmaceutical or supplier companies, the proxy investors, and the investment bankers–in whole of APAC. According to Frost & Sullivan the Indian pharma market was valued at US$ 8.8 billion in FY2007. With numerous patented drugs losing their patent protection in coming years, India promises to be a great place for producing and selling generics. The India opportuniy is not restricted to a few top global pharmaceuticals only, but also for small and mid-sized firms looking for an ideal high growth market. The SMEs contribute close to 49 percent to India’s total pharma revenues. The new entrants can exploit the huge OTC space to gain some quick visibility and market share.
In this special, you will read about the opportunities in Contract Research and Manufacturing Services space where India can reduce the drug R&D and manufacturing costs and their the time-to-market. India not only offers cost arbitrage but also a huge pool of scientific and research professionals. We have also featured here the trends in the huge OTC space and the funding options for small and medium sized companies. Plus a piece on ‘Ion exchange resins’ and a feature on pre-filled syringes.Happy reading. Enjoy your stay and sight seeing at Shanghai.